Salute in Horizon 2020: Giornata Nazionale di Lancio dei bandi

Transcription

1 Salute in Horizon 2020: Giornata Nazionale di Lancio dei bandi Collaborazione tra Università e Industria in un progetto europeo "Innovation 2" del Settimo Programma Quadro (FP7): THINPAD - Maurizio Botta - Università degli Studi di Siena 3 Dicembre 2013, Roma

2 Prof. Maurizio Botta Laurea cum laude in Chemistry at University of Rome PhD Università del New Brunswick, Canada (Prof. Wiesner) Researcher at University of Rome (Prof. Nicoletti) Post-doc at Montreal (Prof. Hanessian) Professore Associato, University of Siena Professore Ordinario, University of Siena -- Member Editorial board of ACS J. Med. Chem., ChemMedChem -- Adjunt Professor Sbarro Institute for Cancer Research and Molecular Medicine Temple University, Philadelphia, USA Google scholar CITATION REPORT Number of publications: 430 Number of Patents: 15 Number of citations: 5917 h-index: 37 i10-index: 210

3 University of Siena Dipartimento di Biotecnologie, Chimica e Farmacia -Polo Scientifico San Miniato Via Aldo Moro SIENA, Italy The Dipartimento di Biotecnologie, Chimica e Farmacia of Siena University was created in It is situated within the Scientific Area of the San Miniato University Campus, where the majority of the scientific and educational institutions are housed and where to it moved in 1999 from its previous location at the centre of Siena.

4 Expertise Combined application of Molecular Modeling, Combinatorial Chemistry and Analytical Techniques to Speed-up the Lead Discovery Process Primary libraries Molecular Modeling Combinatorial Chemistry Focused libraries Solid-phase synthesis Parallel synthesis Asymmetric synthesis Biotransformation using enzymes Microwave-assisted synthesis Disease selection Gene to function Function to Target Target to Hit Hit to Lead Lead optimisation Pre-dev. compound Phase I Phase II Phase III Phase IV milligrams grams kilos

5 Overview of the Botta s Research Group Design and Synthesis of Hit Compounds Hit to Lead Optimization Theoretical Study on Target Proteins ADMET properties Molecular Modeling Virtual Screening Pharmacophore modeling Molecular Dynamics ADMET prediction Organic Synthesis Microwave-assisted Click-chemistry Natural compounds synthesis Combinatorial chemistry Analytical Chemistry & Toxicology ADMET properties Membrane permeation Drug metabolism (liver)

6 Main Research Areas HIV/AIDS -Reverse Transcriptase -Integrase -ENTRY -NCp7 Infectious disorders Tuberculosis -Zmp1 -PtpB -pyrazoles -pyrazolopyrimidin-7-ones Kinetoplastid diseases -T. cruzi Tryp.Reductase -L. infantum Tryp.Reductase -T. cruzi G6PDH -T. cruzi CYP51 Cancer Fungal/bacterial infections -macrocyclic amidoguanidines -linear guanidines Leukemia Neuroblastoma Medulloblastoma..

7 EU Projects involvement FLUCURE (HEALTH Novel therapeutics against influenza. FP7-INFLUENZA-2010), Project reference: from 01/2010 to 01/2014 Design of MSAAs. Research Training Network (HPRN-CT ) Design and Synthesis of Novel Paclitaxel (Taxol ) Mimics Using a Common Pharmacophore Model for Microtubule-Stabilizing Agents (MSAAs) 09/ /2004 TRIoH Targeting Replication and Integration of HIV- 6th Framework Programme LSHB CT , from 01/2004 to 06/2007; ExCellENT-HIT Exploiting Cellular Transport of Nuclear Transcripts as HIV Innovative Therapy LSHP-CT / /2008; THINC Targeting hiv integration co-factors, targeting cellular proteins during nuclear import or integration of hiv 7th Framework Programme-HEALTH from 03/2008 to 02/2012; CHAARM Combined Highly Active Anti-retroviral Microbicides 7th Framework Programme from 01/2010 to 01/2015;

8 COST Action Involvment CM0602 Inhibitors of Angiogenesis: Design, Synthesis and Biological Exploration (ANGIOKEM). CM0801 New Drugs for Neglected Diseases CM0804 Chemical Biology with Natural Products. CM1106 Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells. CM1307 Targeted Chemoterapy Towards Disease caused by endoparasites.

9 FP7-HEALTH-2013 Proposal full title: Imaging technologies for detection, diagnosis and therapy of neuroblastoma Proposal acronym: ImagTechNB Work programme topics addressed: HEALTH : Development of imaging technologies for therapeutic interventions in rare diseases Coordinator: Università degli Studi di Siena (Prof. Maurizio Botta) Writing collaborator: Dr. Giorgio Maccari Proposal full title: Targeting Kinetoplastid Diseases Proposal acronym: TarKinD Work programme topics addressed: HEALTH : Drug development for neglected parasitic diseases Coordinator: Università degli Studi di Siena (Prof. Maurizio Botta) Writing collaborator: Dr. Francesca Moraca Proposal full title: Targeting the HIV-1 Nucleocapsid Protein to Fight Antiretroviral Drug Resistance Proposal acronym: THINPAD Work programme topics addressed: HEALTH : Drugs and vaccines for infections that have developed or are at risk of developing significant anti-microbial resistance Coordinator: Università degli Studi di Siena (Prof. Maurizio Botta) Writing collaborator: Dr. Mattia Mori

10 STAGE 1 Proposal full title: Imaging technologies for detection, diagnosis and therapy of neuroblastoma Proposal acronym: ImagTechNB Work programme topics addressed: HEALTH : Development of imaging technologies for therapeutic interventions in rare diseases Coordinator: Università degli Studi di Siena (Prof. Maurizio Botta) Writing collaborator: Dr. Giorgio Maccari Proposal full title: Targeting Kinetoplastid Diseases Proposal acronym: TarKinD Work programme topics addressed: HEALTH : Drug development for neglected parasitic diseases Coordinator: Università degli Studi di Siena (Prof. Maurizio Botta) Writing collaborator: Dr. Francesca Moraca Proposal full title: Targeting the HIV-1 Nucleocapsid Protein to Fight Antiretroviral Drug Resistance Proposal acronym: THINPAD Work programme topics addressed: HEALTH : Drugs and vaccines for infections that have developed or are at risk of developing significant anti-microbial resistance Coordinator: Università degli Studi di Siena (Prof. Maurizio Botta) Writing collaborator: Dr. Mattia Mori

11 STAGE 2 Proposal full title: Imaging technologies for detection, diagnosis and therapy of neuroblastoma Proposal acronym: ImagTechNB Work programme topics addressed: HEALTH : Development of imaging technologies for therapeutic interventions in rare diseases Coordinator: Università degli Studi di Siena (Prof. Maurizio Botta) Proposal full title: Targeting Kinetoplastid Diseases Proposal acronym: TarKinD Work programme topics addressed: HEALTH : Drug development for neglected parasitic diseases Coordinator: Università degli Studi di Siena (Prof. Maurizio Botta) Writing collaborator: Dr. Francesca Moraca Proposal full title: Targeting the HIV-1 Nucleocapsid Protein to Fight Antiretroviral Drug Resistance Proposal acronym: THINPAD Work programme topics addressed: HEALTH : Drugs and vaccines for infections that have developed or are at risk of developing significant anti-microbial resistance Coordinator: Università degli Studi di Siena (Prof. Maurizio Botta) Writing collaborator: Dr. Mattia Mori

12 Targeting the HIV-1 Nucleocapsid Protein to fight Antiretroviral Drug Resistance

13 THINPAD website is online

14 THINPAD Partners 8 th IRNCS Barcelona th IRNPAS Montreal 2013

15 SMEs in THINPAD -IRBM Science Park ( -ViroStatics ( Active collaborations with SMEs, even before THINPAD HIV Cancer Other disease SMEs participated to writing and editing the THINPAD proposal The THINPAD Business Plan has been elaborated by SMEs and discussed with other THINPAD parties

16 THINPAD Budget SMEs oriented Academic partner Academic partner Academic partner SME partner SME partner INNOVATION-2 SMEs shall request > 50% of total budget

17 THINPAD Management & Decision Making Structure

18 THINPAD WPs Overview

19 THINPAD Coordination Research activity WP2 to WP6 Two coordination workpackages strictly connected with research workpackages

20 THINPAD Research Work Plan Step1: LEAD SELECTION

21 THINPAD Research Work Plan Step2: preclinical studies

22 THINPAD Business Plan - highlights Step 1 completion of first-in-man enabling studies Phase 1 Clinical study Managed by THINPAD SMEs [1-2 years starting from the end of the project (August 2016)] Step2 manufacturing, commercialization marketing rights Out-licensing to Pharmaceutical Companies [starting from the end of 2017]

23 in house - SMEs Outlicensing to big Pharma The Objective is to secure THINPAD NCIs a codevelopment/license deal by 2018 the economic potential of the project

24